Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kasey L Couts

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
Therapeutic Advances in Medical Oncology|June 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival updateJessica S W Borgers, Theresa M Medina, William A Robinson, et al.
Cell Death & Disease|September 7, 2018
BH3 mimetics induce apoptosis independent of DRP-1 in melanomaNabanita Mukherjee, Andrew Strosnider, Bay Vagher, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Immunohorizons|February 20, 2020
High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell ChangesJessica S W Borgers, Richard P Tobin, Victoria M Vorwald, et al.
Molecular Cell|April 14, 2009
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanomaWilliam M Old, John B Shabb, Stephane Houel, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
Therapeutic Advances in Medical Oncology|June 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival updateJessica S W Borgers, Theresa M Medina, William A Robinson, et al.
Cell Death & Disease|September 7, 2018
BH3 mimetics induce apoptosis independent of DRP-1 in melanomaNabanita Mukherjee, Andrew Strosnider, Bay Vagher, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Immunohorizons|February 20, 2020
High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell ChangesJessica S W Borgers, Richard P Tobin, Victoria M Vorwald, et al.
Molecular Cell|April 14, 2009
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanomaWilliam M Old, John B Shabb, Stephane Houel, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Pageof 4